Vigil Neuroscience, Inc. ( (VIGL) ) has released its Q4 earnings. Here is a breakdown of the information Vigil Neuroscience, Inc. presented to its investors.
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by utilizing microglia, the brain’s sentinel immune cells, to create precision-based therapies. The company recently announced its financial results for the fourth quarter and full year of 2024, alongside significant advancements in its clinical programs. Vigil reported positive Phase 1 data for VG-3927, a small molecule TREM2 agonist for Alzheimer’s Disease, and plans to initiate a Phase 2 trial in the third quarter of 2025. Additionally, the company is on track to report final analysis from the IGNITE Phase 2 trial of iluzanebart for ALSP in the second quarter of 2025, with intentions to pursue accelerated approval. Financially, Vigil ended 2024 with $97.8 million in cash and equivalents, expecting this to fund operations into 2026. R&D expenses increased due to clinical activities, while G&A expenses slightly decreased. The net loss for 2024 was $84.3 million, reflecting ongoing investment in clinical development. Looking forward, Vigil is poised for a pivotal year with upcoming trial results and potential regulatory advancements, maintaining a strong cash position to support its strategic goals.